Japanese Pharmacology & Therapeutics（JPT）
Vol. 31 Suppl. 1 2003
Opening Remarks
H. Kawasaki
Jpn Pharmacol Ther 2003 31（s1) 3
Liver cirrhosis（HCV）after viral disappearance
M. Hirano, et al.
Jpn Pharmacol Ther 2003 31（s1) 9
C. Koreeda
Jpn Pharmacol Ther 2003 31（s1) 15
No relation between atherosclerosis and cerebral vascular resistance in chronic liver disease
M. Kawakami,, et al.
Jpn Pharmacol Ther 2003 31（s1) 23
The usefulness of the interventional radiology for portal－systemic encephalopathy
T. Nakazawa
Jpn Pharmacol Ther 2003 31（s1) 29
【Discussion 1～4】
Jpn Pharmacol Ther 2003 31（s1) 35
Effects of renin－angiotensin system on liver fibrosis
K. Kanno, et al.
Jpn Pharmacol Ther 2003 31（s1) 41
Hepatic expression of alkaline phosphatase（ALP）in human livers of primary biliary cirrhosis（PBC）
N. Suzuki, et al.
Jpn Pharmacol Ther 2003 31（s1) 45
Serum thioredoxin levels reflect the oxidative state of nonalcoholic steatohepatitis and simple steatosis
M. Furutani, et al.
Jpn Pharmacol Ther 2003 31（s1) 49
SH. Kawa, et al.
Jpn Pharmacol Ther 2003 31（s1) 53
【Discussion 5～8】
Jpn Pharmacol Ther 2003 31（s1) 59
Protective effects of endotoxin－induced nitric oxide on acetaminophen－induced heptotoxicity
K. Mikami, et al.
Jpn Pharmacol Ther 2003 31（s1) 63
Molecular defects in the ferrochelatase gene in Japanese patients of erythropoietic protoporphyria with severe liver complications
N. Maeda, et al.
Jpn Pharmacol Ther 2003 31（s1) 67
A one year and 3 months experience of counselling porphyrias in our hospital
Y. Horie, et al.
Jpn Pharmacol Ther 2003 31（s1) 73
【Discussion 9～11】
Jpn Pharmacol Ther 2003 31（s1) 77
Hepatic uptake mechanism of pitavastatin by OATP2－and
OATP8 expressed cells and human hepatocytes
M. Hirano, et al.
Jpn Pharmacol Ther 2003 31（s1) 81
Analysis of the human hepatic uptake mechanism
of ursodeoxycholic acid and its conjugates
K. Maeda, et al.
Jpn Pharmacol Ther 2003 31（s1) 85
The transcriptional regulations of the liver－specific organic
anion
transporter－2 in Hep3B cell
H. Ohtsuka, et al.
Jpn Pharmacol Ther 2003 31（s1) 89
Polymorphisms of two anion transporters（OATP－C and MRP2）genes
－Consequences for pravastatin pharmacokinetics－
I. Ieiri, et al.
Jpn Pharmacol Ther 2003 31（s1) 95
Functional analysis of SNPs in human OATP2（OATP－C／SLC21A6）
M. Iwai, et al.
Jpn Pharmacol Ther 2003 31（s1) 101
【Discussion 12～16】
Jpn Pharmacol Ther 2003 31（s1) 105
Bilirubin production and hemeoxygenase－1 expression in ischemia－reperfused rat liver in vivo
T. Kobayashi, et al.
Jpn Pharmacol Ther 2003 31（s1) 109
Expression of organic anion transporters in liver and kidneys of eisai hyperbilirubinuria rats（EHBR）
M. Kuroda, et al.
Jpn Pharmacol Ther 2003 31（s1) 119
Biliary excretion of azelnidipine in the rat
N. Hanawa, et al.
Jpn Pharmacol Ther 2003 31（s1) 123
Identification of a novel 2026G＞C（G676R）mutation of the MRP2 gene in a Japanese patient with Dubin－Johnson syndrome
I. Machida, et al.
Jpn Pharmacol Ther 2003 31（s1) 125
【Discussion 15～17】
Jpn Pharmacol Ther 2003 31（s1) 131
Expression of Mrp2 and Mrp3 during liver regeneration after 90％ partial hepatectomy in rats
TH. Chang, et al.
Jpn Pharmacol Ther 2003 31（s1) 133
Expression and localization of hepatobiliary transporters and radixin in primary biliary cirrhosis
H. Kojima, et al.
Jpn Pharmacol Ther 2003 31（s1) 137
I. Nakagome, et al.
Jpn Pharmacol Ther 2003 31（s1) 143
A drug transporter database for research in pharmacokinetics of drugs
Y .Yokono, et al.
Jpn Pharmacol Ther 2003 31（s1) 151
【Discussion 21～24】
Jpn Pharmacol Ther 2003 31（s1) 157
S.Kishino, et al.
Jpn Pharmacol Ther 2003 31（s1) 161
【Discussion 25】
Jpn Pharmacol Ther 2003 31（s1) 165
Closing Remarks
T. Kamataki
Jpn Pharmacol Ther 2003 31（s1) 167